Environmental Health Experts Meet: Grants on the Agenda
Published Date: 8/19/2025
Notice
Summary
The National Institute of Environmental Health Sciences is holding a hybrid meeting from November 16-18, 2025, where experts will review grant applications and chat with researchers. Some parts are open to the public online, while others are private to protect personal info. This meeting affects scientists seeking funding and anyone interested in environmental health research updates.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Open Sessions Videocast Available
You can watch the meeting's open sessions online via the NIH Videocasting website (http://videocast.nih.gov/). The open videocast covers portions of the hybrid meeting on November 17-18, 2025, and is available to the public while in-person attendance is limited to space available.
Grant Reviews Held in Closed Sessions
Portions of the meeting on November 16-18, 2025 are closed to the public to review and evaluate individual grant applications and to consider personnel qualifications and investigator competence. These closed sessions protect personal privacy by keeping those grant review discussions private.
In-Person Attendance Limits and Accommodations
In-person attendance is limited to space available at the NIEHS Rodbell Auditorium for the November 16-18, 2025 hybrid meeting, and people who need special assistance (for example, sign language interpretation) should notify the Contact Person in advance. Visitors to the campus must follow NIH visitor security procedures and show one form of identification when attending on-site.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Previous / Next Documents
Previous: 2025-15797, Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help drug makers find the best doses for cancer-fighting radiopharmaceuticals during testing. This means companies can develop safer, more effective treatments before asking to sell them. If you’re in the cancer drug game, this guide is your new playbook—expect smoother approvals and smarter dosing decisions soon!
Next: 2025-15799, Lessons Learned From the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Public Workshop; Request for Comments
The FDA is hosting a virtual workshop to share what they’ve learned from a special pilot program that helps speed up the chemistry and manufacturing steps for new drugs. This affects drug makers and patients waiting for faster access to promising treatments. The workshop will gather feedback to improve future policies, aiming to make drug development quicker and smoother without extra costs or delays.